Conclusions
In this large retrospective study, the prevalence of most maternal and infant outcomes was similar with different antihypertensive medications. A significantly lower risk of SGA was seen for methyldopa than labetalol, which is noteworthy because methyldopa is not preferred in US or UK guidelines.6,7Our results suggest that methyldopa may warrant additional consideration, especially in pregnancies for which there is heightened concern about growth restriction.